Clinical Trials
- Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients
- Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients
- Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism
- Punchgrafting Techniques for Vitiligo
- 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
- A Novel Argon Laser Iridoplasty for Pigment Dispersion Syndrome
- Cause of Pigment Dispersion Syndrome
- Continuous Intraocular Pressure (IOP) Monitoring in Pigmentary Dispersion Syndrome and Pigmentary Glaucoma Patients
- Pigment Dispersion Syndrome: Natural History and Possible Protective Effect of a YAG Laser Iridotomy
- The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure
- A Study of Pentosan Polysulfate Sodium and the Development of Pigmentary Maculopathy and Pigmentary Retinopathy
- Cellular Scale Measures of Short-Term Retinal Atrophy Progression
- Impact of Visual Field Restriction on Visual Exploration
- Mobility Protocol Adapted for Advanced Visually Impaired Subjects
- Self-confidence Study in Patients With Argus II Artificial Retina
- 3D Craniofacial Morphologic Development of Healthy Infants
- Cranial Cup Use for the Prevention of Positional Head Shape Deformity in the NICU
- Cranial Orthotic Device Versus Repositioning Techniques for the Management of Plagiocephaly: the CRANIO Randomized Trial
- Efficacy of Pediatric Manual Therapy in the Positional Plagiocephaly
- Hanger Helmet Study
- Newborn Head Molding and Later Asymmetries
- Postural Assessment in Plagiocephaly
- Premie Pouch to Manage Deformational Plagiocephaly in Very Low Birth Weight Infants
- a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients
- A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma
- A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma
- Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
- Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia
- Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
- Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Collection and Storage of Tissue and Blood Samples From Patients With Cancer
- Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
- Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia
- Expanded Access to Venetoclax
- Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia
- Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
- Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia
- Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation
- Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)
- Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen
- Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients
- Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
- Non Invasive Diagnosis of Pneumocystis Pneumonia
- Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center
- Prospective Observational Study on the Incidence of Opportunistic Fungal Infections
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS
- A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
- A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab
- Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial
- Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
- POEMS Syndrome Treatment With Lenalidomide
- Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome
- The Treatment of Lenalidomide in Patients With POEMS Syndrome
- To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope
- 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants
- A Campaign-based ID fIPV Administration Trial
- A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a ‘1+2’ Sequential Schedule With bOPV in Infants
- A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a “2+1″Sequential Schedule With bOPV in Infants
- A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates
- A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children
- A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China
- A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants
- A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.
- A Study of the Safety of IMOVAX Polio™ in China
- A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China
- A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV
- A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine
- A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2
- A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age
- A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania
- An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses
- An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants
- Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine
- Assessment of Poliovirus Type 2 Immunogenicity of One and Two Dose Schedule With IPV and fIPV When Administered at 9-13 Months of Age in Bangladesh
- Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV
- Clinical Trial of Novel OPV2 Vaccine
- Community Engagement and Conditional Incentives to Accelerate Polio
- Comparison of Immune Response Using 2 Vaccination Schedules Using Inactivated Polio Vaccine
- Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan
- Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally
- Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain
- Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization
- Diarrhea and Bivalent Oral Polio Vaccine Immunity
- Duration of IPV Priming and Antibody Decay
- Effect of Ankle-foot Orthoses on Balance Confidence
- Effect of Digital Payment to Campaign Health Workers on Vaccination Coverage
- Effect of Lactoferrin on Polio Seroconversion
- Effect of Zinc Supplementation on Response to Oral Polio Vaccine in Infants in Pakistan
- Environmental Surveillance (ES) for Polio and AMR Using the TaqMan Array Card
- Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh
- Evaluation of Integrating MIYCN Interventions in Existing CGPP of PCI
- Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine
- Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant
- Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio Vaccine
- Evaluation of the Persistence of the Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovac®) by Measuring the Response to an Additional Dose of IPV-Al AJV
- Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study
- Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants
- Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly
- Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months
- Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers
- Immunogenicity and Safety of Fractional Doses of IPV Intradermally vs Full Doses Intramuscularly
- Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV
- Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine
- Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China
- Immunogenicity and Safety Study of GlaxoSmithKline Biologicals’ Poliorix™ Vaccine
- Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine
- Immunogenicity of Inactivated and Live Polio Vaccines
- Immunogenicity of Intramuscular and Intradermal IPV
- Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine
- Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine
- Inactivated Poliomyelitis Vaccine Made From Sabin Strain
- Inactivated Poliovirus Vaccine (IPV) With or Without dmLT Challenge Study in Healthy Adults
- Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules
- Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT
- IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults
- Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine
- Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study
- nOPV2 and bOPV Trial
- Observational Program, Double-blind, Placebo-controlled to Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19
- OPV Transmissibility in Communities After Cessation of Routine OPV Immunization
- Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3
- Persistence of IPV Immunity
- Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in IPV Primed Adults
- Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults
- Physical Activity in People With Sequelae of Poliomyelitis
- Polio End-game Strategies – Poliovirus Type 2 Challenge Study
- Polio NID and Routine EPI Integration Trial Pakistan
- Quality of Life in Adult Neurological Patients
- Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns
- Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine
- Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine
- Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults
- Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants
- Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine
- Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)
- Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months
- Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age
- Safety and Immunogenicity of IPOVAC in Young Children
- Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals’ IPV Vaccine (PoliorixTM) in Toddlers
- Safety and Reactogenicity of GSK Biologicals’ Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants
- Safety of Imovax Polio in Chinese Infants and Children
- Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants
- Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life
- Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine
- Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China
- Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine
- Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine
- Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh
- Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
- Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan
- Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
- Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan
- Study to Evaluate Eupolio(IPV)’s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants
- Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants
- The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains
- The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)
- The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)
- The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)
- To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan
- Trail To Evaluate the Immune Effects of Primary and Booster Immunizations With Poliovirus Vaccine